Biodesix Inc. Reports Q1 2025 Results Amid Stock Volatility and Focus on Diagnostic Innovations
Biodesix Inc. has announced its first-quarter 2025 results, with its stock price experiencing a significant drop from its 52-week high, but the company remains committed to advancing its mission in diagnostic capabilities in oncology.
2 minutes to read